AI-generated analysis. Always verify with the original filing.
Outlook Therapeutics, Inc. reported Q1 FY2026 financial results with GAAP net loss of $23.1 million ($0.38 per share) and adjusted net loss of $13.5 million ($0.22 per share), alongside LYTENAVA commercial expansion in Europe including Austria launch and planned launches in Ireland and Netherlands in 2026. The company requested a Type A FDA meeting to address ONS-5010 BLA CRL.
Event Type
Disclosure
Mandatory
Variant
8-K
and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release dated February 17, 2026 104 Cover Page Interactive Data File (embedded
| Metric | Value | Basis |
|---|---|---|
| Revenues, net | $-1.2K | GAAP |
| Net loss attributable to common stockholders | $-23.1K | GAAP |
| Net loss per share basic and diluted | $-0.38 | GAAP |
| Adjusted net loss attributable to common stockholders | $-13.5K | Non-GAAP |
| Adjusted net loss per share basic and diluted | $-0.22 | Non-GAAP |